Neridronate
Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB) . Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2].
Product Specifications
CAS Number
79778-41-9
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/neridronate.html
Purity
98.0
Solubility
H2O : 5 mg/mL (ultrasonic; warming; adjust pH to 8 with NaOH; heat to 60°C)
Smiles
OC(P(O)(O)=O)(CCCCCN)P(O)(O)=O
Molecular Formula
C6H17NO7P2
Molecular Weight
277.15
Precautions
H302, H315, H319, H335
References & Citations
[1]Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47.|[2]Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
G4298 96 Tests
Protein transport protein Sec24A (SEC24A) Mouse ELISA Kit
Sign In for Pricing
View Details